LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 118

Search options

  1. Article ; Online: Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance.

    Barton, Blaire E / Chau, Cindy H / Figg, William D

    Trends in cancer

    2022  Volume 8, Issue 8, Page(s) 629–631

    Abstract: Checkpoint blockade and adoptive T cell therapy are efficacious in some patients, but many do not respond to these immunotherapies. Chou et al. recently elucidated the characteristics of a new cell population with greater cytotoxicity, improved tumor ... ...

    Abstract Checkpoint blockade and adoptive T cell therapy are efficacious in some patients, but many do not respond to these immunotherapies. Chou et al. recently elucidated the characteristics of a new cell population with greater cytotoxicity, improved tumor homing, and reduced exhaustion compared to conventional cytotoxic T cells. These cells may improve the efficacy of cancer immunotherapies, especially for patients refractory or unresponsive to current approaches.
    MeSH term(s) Humans ; Immunotherapy, Adoptive ; Monitoring, Immunologic ; Neoplasms/immunology ; Neoplasms/therapy ; T-Lymphocytes, Cytotoxic
    Language English
    Publishing date 2022-06-04
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Intramural ; Comment
    ZDB-ID 2852626-0
    ISSN 2405-8025 ; 2405-8033 ; 2405-8033
    ISSN (online) 2405-8025 ; 2405-8033
    ISSN 2405-8033
    DOI 10.1016/j.trecan.2022.05.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Single whole genome sequencing analysis blazes the trail for precision medicine.

    Napoli, Giulia C / Chau, Cindy H / Figg, William D

    Cancer biology & therapy

    2022  Volume 23, Issue 1, Page(s) 134–135

    Abstract: As precision oncology evolves toward developing more targeted therapies, sequencing has moved to the forefront of treatment decision-making. Whole genome sequencing (WGS) has emerged as a technology capable of identifying candidates for rare and targeted ...

    Abstract As precision oncology evolves toward developing more targeted therapies, sequencing has moved to the forefront of treatment decision-making. Whole genome sequencing (WGS) has emerged as a technology capable of identifying candidates for rare and targeted treatments. Yet, because the tumor is constantly evolving during relapse and therapy resistance, the frequency with which WGS should be performed to identify potential new therapies for progressing patients remains unknown. A recent study in
    MeSH term(s) Biomarkers, Tumor/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Mutation ; Neoplasm Recurrence, Local ; Precision Medicine ; Whole Genome Sequencing
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2022-02-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Intramural
    ZDB-ID 2146305-0
    ISSN 1555-8576 ; 1538-4047
    ISSN (online) 1555-8576
    ISSN 1538-4047
    DOI 10.1080/15384047.2022.2033058
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5887: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Functional Drug Screening in the Era of Precision Medicine.

    Napoli, Giulia C / Figg, William D / Chau, Cindy H

    Frontiers in medicine

    2022  Volume 9, Page(s) 912641

    Abstract: The focus of precision medicine is providing the right treatment to each unique patient. This scientific movement has incited monumental advances in oncology including the approval of effective, targeted agnostic therapies. Yet, precision oncology has ... ...

    Abstract The focus of precision medicine is providing the right treatment to each unique patient. This scientific movement has incited monumental advances in oncology including the approval of effective, targeted agnostic therapies. Yet, precision oncology has focused largely on genomics in the treatment decision making process, and several recent clinical trials demonstrate that genomics is not the only variable to be considered. Drug screening in three dimensional (3D) models, including patient derived organoids, organs on a chip, xenografts, and 3D-bioprinted models provide a functional medicine perspective and necessary complement to genomic testing. In this review, we discuss the practicality of various 3D drug screening models and each model's ability to capture the patient's tumor microenvironment. We highlight the potential for enhancing precision medicine that personalized functional drug testing holds in combination with genomic testing and emerging mathematical models.
    Language English
    Publishing date 2022-07-08
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2022.912641
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book: Drug management of prostate cancer

    Figg, William D. / Chau, Cindy H. / Small, Eric J.

    2010  

    Author's details William D. Figg ; Cindy H. Chau ; Eric J. Small
    Language English
    Size XVII, 428 S. : Ill., graph. Darst., 26 cm
    Publisher Springer
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT016566469
    ISBN 978-1-60327-831-7 ; 1-60327-831-1 ; 9781603278294 ; 160327829X
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2010 A 5438 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Targeting the metastatic niche: Single-cell lineage tracing in prime time.

    Sommer, Elijah R / Napoli, Giulia C / Chau, Cindy H / Price, Douglas K / Figg, William D

    iScience

    2023  Volume 26, Issue 3, Page(s) 106174

    Abstract: Identification of actionable drug targets remains a rate-limiting step of, and one of the most prominent barriers to successful drug development for metastatic cancers. CRISPR-Cas9, a tool for making targeted genomic edits, has given rise to various ... ...

    Abstract Identification of actionable drug targets remains a rate-limiting step of, and one of the most prominent barriers to successful drug development for metastatic cancers. CRISPR-Cas9, a tool for making targeted genomic edits, has given rise to various novel applications that have greatly accelerated discovery in developmental biology. Recent work has coupled a CRISPR-Cas9-based lineage tracing platform with single-cell transcriptomics in the unexplored context of cancer metastasis. In this perspective, we briefly reflect on the development of these distinct technological advances and the process by which they have become integrated. We also highlight the importance of single-cell lineage tracing in oncology drug development and suggest the profound capacity of a high-resolution, computational approach to reshape cancer drug discovery by enabling identification of novel metastasis-specific drug targets and mechanisms of resistance.
    Language English
    Publishing date 2023-02-10
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2589-0042
    ISSN (online) 2589-0042
    DOI 10.1016/j.isci.2023.106174
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article: PARP inhibitors on the move in prostate cancer: spotlight on Niraparib & update on PARP inhibitor combination trials.

    Beatson, Erica L / Chau, Cindy H / Price, Douglas K / Figg, William D

    American journal of clinical and experimental urology

    2022  Volume 10, Issue 4, Page(s) 252–257

    Abstract: PARP inhibitors were recently introduced as a novel targeted therapy for biomarker positive metastatic castration resistant prostate cancer (mCRPC) patients, a population that inevitably acquires resistance to existing standard care regimens. Olaparib ... ...

    Abstract PARP inhibitors were recently introduced as a novel targeted therapy for biomarker positive metastatic castration resistant prostate cancer (mCRPC) patients, a population that inevitably acquires resistance to existing standard care regimens. Olaparib and rucaparib are now FDA-approved for mCRPC, while talazoparib and niraparib are advancing through the clinical stage of development. We highlight the recent results of the GALAHAD trial testing the efficacy of niraparib in mCRPC patients with DNA damage repair gene defects and compare its performance to key PARP inhibitor trials (PROFOUND, olaparib; TRITON2, rucaparib; TALAPRO-1, talazoparib). Finally, we briefly discuss recent updates on emerging PARP inhibitor and androgen receptor targeting combination trials as a novel treatment strategy for upfront treatment of mCRPC and in earlier disease settings.
    Language English
    Publishing date 2022-08-15
    Publishing country United States
    Document type Journal Article
    ISSN 2330-1910
    ISSN 2330-1910
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome.

    Lee, Kristi Y / Chau, Cindy H / Price, Douglas K / Figg, William D

    Cancer biology & therapy

    2022  Volume 23, Issue 1, Page(s) 136–138

    Abstract: The vast majority of the human proteome is yet to be functionally characterized thus hindering ongoing investigations on potential drug resistance mechanisms and advanced treatment options. Chemical proteomics is a powerful solution for enzyme profiling ... ...

    Abstract The vast majority of the human proteome is yet to be functionally characterized thus hindering ongoing investigations on potential drug resistance mechanisms and advanced treatment options. Chemical proteomics is a powerful solution for enzyme profiling and the development of next generation cancer therapeutics previously deemed undruggable by small molecules. Within this field, activity-based protein profiling (ABPP) is a specialized technology capable of discriminating enzyme interactions that occur within complex, biological environments. In a recent publication by Lovell et al, the kallikrein-related peptidase (KLK) family of serine proteases that is highly implicated in the progression of prostate cancer (PCa) was subject to ABPP to elucidate enzymatic activities in the presence of enzalutamide. This is the first report of ABPP in PCa and of activity-based chemical probes selective for individual KLKs. Further, the study reveals androgen receptor-dependent activity among KLK proteins, particularly in mediating the invasion of the bone microenvironment.
    MeSH term(s) Humans ; Kallikreins/chemistry ; Kallikreins/metabolism ; Kallikreins/therapeutic use ; Male ; Prostatic Neoplasms/enzymology ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Proteomics ; Tumor Microenvironment
    Chemical Substances Kallikreins (EC 3.4.21.-)
    Language English
    Publishing date 2022-02-07
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2146305-0
    ISSN 1555-8576 ; 1538-4047
    ISSN (online) 1555-8576
    ISSN 1538-4047
    DOI 10.1080/15384047.2022.2033059
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5887: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Revisiting 5α-reductase inhibitors and the risk of prostate cancer.

    Chau, Cindy H / Figg, William D

    Nature reviews. Urology

    2018  Volume 15, Issue 7, Page(s) 400–401

    MeSH term(s) 5-alpha Reductase Inhibitors/therapeutic use ; Chemoprevention/methods ; Humans ; Male ; Neoplasm Staging ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/prevention & control ; Risk Factors
    Chemical Substances 5-alpha Reductase Inhibitors
    Language English
    Publishing date 2018-05-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2493737-X
    ISSN 1759-4820 ; 1759-4812
    ISSN (online) 1759-4820
    ISSN 1759-4812
    DOI 10.1038/s41585-018-0018-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6030: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Diversity on demand: multi-ancestry meta-analysis improves genetic risk prediction in prostate cancer.

    Leon, Andres F / Chau, Cindy H / Price, Douglas K / Figg, William D

    American journal of clinical and experimental urology

    2021  Volume 9, Issue 2, Page(s) 189–193

    Abstract: Several genome-wide association studies have been conducted to identify genetic risk factors associated with prostate cancer, but their ability to discover new genetic variants and their applicability across ancestry groups have been limited by their ... ...

    Abstract Several genome-wide association studies have been conducted to identify genetic risk factors associated with prostate cancer, but their ability to discover new genetic variants and their applicability across ancestry groups have been limited by their lack of genetic diversity, owing to an underrepresentation of non-European populations. A recent meta-analysis published in
    Language English
    Publishing date 2021-04-15
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2330-1910
    ISSN 2330-1910
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article: Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.

    Doan, David K / Schmidt, Keith T / Chau, Cindy H / Figg, William D

    Cancers

    2021  Volume 13, Issue 9

    Abstract: Prostate cancer has entered into the era of precision medicine with the recent approvals of targeted therapeutics (olaparib and rucaparib). The presence of germline mutations has important hereditary cancer implications for patients with prostate cancer, ...

    Abstract Prostate cancer has entered into the era of precision medicine with the recent approvals of targeted therapeutics (olaparib and rucaparib). The presence of germline mutations has important hereditary cancer implications for patients with prostate cancer, and germline testing is increasingly important in cancer screening, risk assessment, and the overall treatment and management of the disease. In this review, we discuss germline variants associated with inherited predisposition, prostate cancer risk and outcomes. We review recommendations for germline testing, available testing platforms, genetic counseling as well as discuss the therapeutic implications of germline variants relevant to prostate cancer treatments. Understanding the role of germline (heritable) mutations that affect prostate cancer biology and risk as well as the subsequent effect of these alterations on potential therapies is critical as the treatment paradigm shifts towards precision medicine. Furthermore, enhancing patient education tactics and healthcare system infrastructure is essential for the utilization of relevant predictive biomarkers and the improvement of clinical outcomes of patients with prostate cancer or at high risk of developing the disease.
    Language English
    Publishing date 2021-04-29
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13092154
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top